Summit Plc Ticker: Summ.L Market: AIM SP: 132p Market Cap ~£55m Summit is a drug discovery company with two breakthrough drugs in clinical trials. They are due to report results for both in the first half of 2015. The first is a targeted new antibiotic for C-Diff infections - a massive market. It is attracting very favourable terms from regulators and incentives for novel antibiotics. P1 went well and crucially was shown to be highly effective and selective (it does not kill healthy bacteria, which is a huge benefit.) which bodes very well for P2 results. It should attract offers in the hundreds of millions from big pharma at that stage. The second is a disease modifying drug for Duchenne Muscular Dystrophy. It's about to start a new P1 trial with controlled diets to improve absorption. This is an awful, fatal disease with around 50,000 affected boys and young men in the developed world, and this drug pipeline represents real hope for the families as well as a very lucrative opportunity. They are well financed, with £20m in the bank. The company is currently planning for a Nasdaq listing which will almost certainly mean a re-rating, as the US values drug discovery companies much more highly than the UK - and US investors are often reluctant to trade on AIM. The legendary Jim Mellon has a sizeable holding. Upside potential is huge - worth putting a few in your stocking IMHO. AIM shares can now be held in ISAs. * I have shares. I am not providing financial advice. This is just my opinion. I am not responsibile for your actions. Do your own research. Your house may be at risk if you do not keep up repayments on your mortgage.